MedTrace Logo

Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers

NCT00765427 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2009-03-30

No results posted yet for this study

Summary

Healthy volunteer subjects will receive retinoid QLT091001 once-daily for 7 days for safety observation.

Conditions

  • Healthy Human Volunteers

Interventions

DRUG

QLT091001

7-day repeated dose

Sponsors & Collaborators

  • QLT Inc.

    lead INDUSTRY

Principal Investigators

  • Victor Lao, MD

  • Andrew Strong, Ph.D. · QLT Inc.

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00765427 on ClinicalTrials.gov